(Q33376876)

26 July 2017

title

uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer (English)

1 reference

26 July 2017

Ferdinando Mannello

8

0 references

author name string

Wenyi Qin

1

1 reference

26 July 2017

Weizhu Zhu

2

1 reference

26 July 2017

John E Hewett

3

1 reference

26 July 2017

George Rottinghaus

4

1 reference

26 July 2017

Yin-Chieh Chen

5

1 reference

26 July 2017

John T Flynn

6

1 reference

26 July 2017

Beth Kliethermes

7

1 reference

26 July 2017

Edward R Sauter

9

1 reference

26 July 2017

language of work or name

English

0 references

publication date

15 October 2008

1 reference

26 July 2017

1 reference

26 July 2017

volume

8

1 reference

26 July 2017

page(s)

298

1 reference

Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2580770

A urokinase-type plasminogen activator deficiency diminishes the frequency of intestinal adenomas in ApcMin/+ mice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2580770

Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2580770

Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2580770

Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2580770

Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2580770

The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2580770

Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2580770

Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2580770

The urokinase-type plasminogen activator system in cancer metastasis: A review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2580770

A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2580770

Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2580770

Functional evaluation of plasmin formation in primary breast cancer

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-298

Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-298

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-298

Angiogenic inhibition reduces germinal matrix hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-298

Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-298

Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-8-298

Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2580770

The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2580770

In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril

31 October 2018

1 reference

12 December 2020

Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer

1 reference

12 December 2020

Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk

1 reference

12 December 2020

Cyclooxygenase-2 inhibitor ameliorates ureteric damage in rats with obstructed uropathy

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-8-298

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference